IONS Ionis Pharmaceuticals, Inc.

42.91
+1  (2%)
Previous Close 41.87
Open 42.08
Price To book 51.12
Market Cap 5.31B
Shares 123,749,000
Volume 975,250
Short Ratio 4.90
Av. Daily Volume 1,674,430

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b initiation announced March 30, 2017.
AKCEA-APO(a)-LRx
Hyperlipoproteinemia(a) and established cardiovascular disease
Phase 1/2 interim data released November 2016.
IONIS-ANGPTL3-LRx
Cardiovascular disease
Phase 1/2 ongoing
IONIS-DMPK-2.5Rx
Myotonic Dystrophy Type 1 (DM1)
Phase 3 data due 2Q 2017.
IONIS-TTRRx
NEURO-TTR - familial amyloid polyneuropathy (FAP).
Approved December 23, 2016.
SPINRAZA - Nusinersen
Spinal muscular atrophy (SMA)
Phase 2 data released November 2016.
IONIS-FXIRx
End-stage renal disease
Phase 3 data released March 6, 2017 - primary endpoint met. Relative safety concerns noted.
Volanesorsen - APPROACH
Familial chylomicronemia syndrome (FCS)
Phase 2 data released 3Q 2015
IONIS-APO(a)Rx
High lipoprotein(a), or Lp(a)
Phase 2 data released January 4, 2016.
IONIS-GCGRRx
Type 2 diabetes
Phase 3 initiated November 2015
Volanesorsen
Partial lipodystrophy rapidly
Phase 2 released Feb 2015. Achieved statistically significant results but data released was as of 36 weeks rather than 27 weeks for the primary endpoint
IONIS-PTP1BRx
Type 2 diabetes
Phase 3 initiated November 2015
Volanesorsen
Familial partial lipodystrophy (FPL)
Partner GSK announced May 2016 decision not to be proceed with Phase 3 outcome trial
IONIS-TTRRx
CARDIO-TTR - Cardiomyopathy form of TTR amyloidosis.

Latest News

  1. 3 Stocks That Growth Investors Should Love
  2. Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
  3. Biotech Stock Roundup: FDA CRL Hits Incyte, Pipeline Setbacks Weigh on OncoMed
  4. Why the Ionis Spinoff Will Be a Win for Long-Term Investors
  5. Ionis Enters into Collaboration with Ribo to Advance RNA-Targeted Therapeutics in China
  6. Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc.
  7. Why Ionis Pharmaceuticals Dropped 18.7% in March
  8. Questioning Ionis Pharmaceuticals' Spinoff Announcement
  9. Healthcare Winners and Losers Following the AHCA's Failure
  10. My 3 Top Biotech Stocks to Buy Now
  11. Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease
  12. Top Biotech Stocks for Growth Investors
  13. Ionis Pharmaceuticals to Present at Needham Healthcare Conference
  14. Ionis Pharmaceuticals Inc. Doesn't Want to Sell Drugs (Just Profit From Them)
  15. Akcea Therapeutics Announces Three Additions to Board of Directors
  16. Novartis’s Recent Developments
  17. Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering
  18. Lifshitz & Miller LLP Announces Investigation of Air Methods Corporation, Fortress Investment Group LLC, Galena Biopharma, Inc., Ionis Pharmaceuticals, Inc., LMI Aerospace, Inc., Lumos Networks Corp., Silver Bay Realty Trust Corp. and TerraForm Global, Inc.
  19. Recent Developments for Ionis Pharmaceuticals
  20. Ionis’s Subsidiary Akcea Therapeutics and Volanesorsen